Effect of NMN Supplementation on Organ System Biology

Washington University School of Medicine56 enrolled

Overview

The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.

This study is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Enrollment

Conditions

Glucose Metabolism Disorders

Interventions

PlaceboOTHER

Intervention will last at least 16 weeks in the form of two capsules.

TreatmentDIETARY_SUPPLEMENT

Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).

Eligibility

Sex: ALLMin age: 45 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * BMI 25.0-50.0 kg/m² * Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5. Exclusion Criteria: * Women who are still having menses * Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period * Persons who consume moderate-large amounts of caffeine daily (\>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped * Unstable weight (\>3% change during the last 2 months before entering the study)

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Outcomes

Primary Outcomes

Change in Muscle Insulin Sensitivity

The outcome (mean change in muscle sensitivity from baseline to after intervention) will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion after intervention period.

Time frame: After 16 weeks of treatment

Secondary Outcomes

Changes in Glucose Tolerance

The outcome (mean change in oral glucose tolerance from baseline to after intervention) will be assessed during modified oral glucose tolerance test after the intervention

Time frame: After 16 weeks of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.